Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Spectrum Pharmaceuticals, Inc.    SPPI

SPECTRUM PHARMACEUTICALS, INC. (SPPI)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/19/2018 04/20/2018 04/23/2018 04/24/2018 04/25/2018 Date
18.86(c) 18.47(c) 18.26(c) 17.34(c) 17.01 Last
784 926 758 386 1 264 067 1 161 237 1 175 048 Volume
-3.48% -2.07% -1.14% -5.04% -1.90% Change
More quotes
Financials (USD)
Sales 2018 105 M
EBIT 2018 -111 M
Net income 2018 -122 M
Debt 2018 -
Yield 2018 -
Sales 2019 113 M
EBIT 2019 -96,3 M
Net income 2019 -105 M
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales2018 17,8x
Capi. / Sales2019 16,6x
Capitalization 1 876 M
More Financials
Company
Spectrum Pharmaceuticals, Inc. engages in the acquisition, development, and commercialization of pipeline of late-stage clinical and commercial products.It targets non-Hodgkin's lymphoma, advanced metastatic colorectal cancer, acute lymphoblastic leukemia, and multiple myeloma.It operates through... 
More about the company
Surperformance© ratings of Spectrum Pharmaceuticals,
Trading Rating : Investor Rating :
More Ratings
Latest news on SPECTRUM PHARMACEUTICALS,
04/24SPECTRUM PHARMACEUTICALS : Size, Structure Help Poziotinib Pose Threat to Deadly..
AQ
04/23SPECTRUM PHARMACEUTICALS : Announces Publication of Poziotinib Data in Nature Me..
BU
04/23SPECTRUM PHARMACEUTICALS : Highlights Data Showing Poziotinib Overcomes De Novo ..
AQ
04/17SPECTRUM PHARMACEUTICALS : Highlights Data Showing Poziotinib Overcomes De Novo ..
BU
04/16SPECTRUM PHARMACEUTICALS INC : Change in Directors or Principal Officers (form 8..
AQ
04/13SPECTRUM PHARMACEUTICALS : Announces Update of MD Anderson's Phase 2 Data Studyi..
AQ
04/12SPECTRUM PHARMACEUTICALS, INC. : Wired News – Spectrum Pharma Reported Update Da..
AC
04/11SPECTRUM PHARMACEUTICALS : Down Following Positive Cancer Drug Test
AQ
04/11SPECTRUM PHARMACEUTICALS, INC. (NASD : SPPI) Is Running On Some Early Stage Data
AQ
04/11SPECTRUM PHARMACEUTICALS, INC. : Today’s Research Reports on Stocks to Watch: Sp..
AC
More news
Sector news : Biotechnology & Medical Research - NEC
04/25Currency and pricing squeeze GSK as new shingles vaccine shines
RE
04/19Novartis CEO feels heat on U.S. generics, Cosentyx drop
RE
04/17GE rides gene therapy wave with ready-made viral drug factories
RE
04/12GSK slims portfolio with sale of rare disease gene therapy drugs
RE
04/12UK gene therapy firm Orchard plans stock offer after GSK deal
RE
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
04/25Rajesh C. Md Shrotriya Sells 30,000 Shares of Spectrum Pharmaceuticals $SPPI .. 
04/25Spectrum Pharmaceuticals $SPPI Shares Down 5% After Insider Selling  
04/25$SPPI - Spectrum Pharmaceuticals #SPPI Stock Price Down 5% After Insider Sell.. 
04/24Spectrum Pharmaceuticals $SPPI Director Sells $551,100.00 in Stock  
04/24$SPPI New Form 4 for Spectrum Pharmaceuticals, Inc. From our Stock News Alert.. 
More tweets
Qtime:47
News from SeekingAlpha
04/24Looking For Action? S&P 1500 Most Volatile Stocks 
04/19DYNAVAX : Assessing The Underlying Fundamentals Of A Big Winner 
04/18SPECTRUM PHARMACEUTICALS : What To Expect From This Powerful Grower 
04/15PORTFOLIO REVIEW : Continued Market Outperformance In Q1 2018 
04/123 THINGS IN BIOTECH, APRIL 11 : Spectrum's Entree In EGFR, Karyopharm's Rush, On.. 
Chart SPECTRUM PHARMACEUTICALS,
Duration : Period :
Spectrum Pharmaceuticals,  Technical Analysis Chart | SPPI | US84763A1088 | 4-Traders
Technical analysis trends SPECTRUM PHARMACEUTICALS,
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 29,3 $
Spread / Average Target 69%
EPS Revisions
Managers
NameTitle
Joseph W. Turgeon President, Chief Executive Officer & Director
Stuart Mitchell Krassner Chairman
Thomas J. Riga Executive VP, Chief Operating & Commercial Officer
Kurt A. Gustafson Chief Financial Officer & Executive Vice President
Guru Reddy Vice President-Preclinical Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SPECTRUM PHARMACEUTICALS, INC.-8.50%1 876
CELLTRION, INC.--.--%28 789
IQVIA HOLDINGS INC-1.18%20 413
LONZA GROUP-7.22%18 571
INCYTE CORPORATION-28.05%14 432
NEKTAR THERAPEUTICS41.51%13 751